Nabi Pharmaceuticals About
Nabi Pharmaceuticals Nabi Biopharmaceuticals focus is in the
areas of infectious, autoimmune
and addictive
diseases. In addition to four marketed products (PhosLo®, Nabi-HB®, WinRho
SDF®, Aloprim™), the company has several products in various stages of preclinical
and clinical testing. Nabi Biopharmaceuticals has advanced StaphVAX®
to Phase III clinical development. StaphVAX is designed to prevent the most dangerous
and prevalent strains of
Staphylococcus aureus bacterial infections. S. aureus bacteria are
a major cause of hospital-acquired infections and are becoming increasingly resistant
to antibiotics. The company's other products in development include Altastaph™,
an antibody
for prevention and treatment of S. aureus infections, and NicVAX™,
a nicotine vaccine,
both in Phase II clinical testing, and Civacir™, an antibody for preventing
hepatitis
C virus re-infection in liver transplant patients. Product
Pipeline for Nabi Biopharmaceuticals StaphVAX --
Staphylococus infections
NicVax -- Smoking cessation vaccine Civacir -- Hepatitis
C More About Nabi Pharmaceuticals